Menu
← Oncology Approval Tracker
FDA DECISION ·
Calquence
acalabrutinib · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.
LAMPGEN ANALYSIS
Why it matters
The ECHO study brought a BTK inhibitor into first-line chemoimmunotherapy for transplant-ineligible patients.
What research teams should watch
Document transplant eligibility and plan how a continuous oral drug fits around six cycles of chemotherapy.
PRIMARY RECORDS